BioMark Diagnostics Endorses Global Call for Equitable Access to Early Screening on 2026 World Lung Cancer Day Anchored in the 2026 global campaign's core mission of early detection, equitable access to screening, and compassionate patient support, BioMark advances its multi-marker liquid biopsy to ensure no patient is left behind. BioMark continues to work with global healthcare organizations committed to improving lung health through prevention, education, and earlier intervention. World Lung Cancer Day provides an opportunity to recognize the courage of patients and families affected by lung cancer while celebrating the researchers, clinicians, and organizations working tirelessly to reduce the global burden of this disease. About BioMark Diagnostics Inc.BioMark Diagnostics Inc. is a precision diagnostics company dedicated to the early detection of cancer through the analysis of metabolic biomarkers and machine learning algorithms. Forward-Looking Information:This press release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of BioMark Diagnostics Inc.